Allogeneic stem cell transplantation benefits for patients >= 60 years with acute myeloid leukemia and FLT3 internal tandem duplication : a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Show full item record



Permalink

http://hdl.handle.net/10138/233487

Citation

Poire , X , Labopin , M , Polge , E , Passweg , J , Craddock , C , Blaise , D , Cornelissen , J J , Volin , L , Russell , N H , Socie , G , Michallet , M , Fegueux , N , Chevallier , P , Brecht , A , Hunault-Berger , M , Mohty , M , Esteve , J & Nagler , A 2018 , ' Allogeneic stem cell transplantation benefits for patients >= 60 years with acute myeloid leukemia and FLT3 internal tandem duplication : a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation ' , Haematologica , vol. 103 , no. 2 , pp. 256-265 . https://doi.org/10.3324/haematol.2017.178251

Title: Allogeneic stem cell transplantation benefits for patients >= 60 years with acute myeloid leukemia and FLT3 internal tandem duplication : a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Author: Poire, Xavier; Labopin, Myriam; Polge, Emmanuelle; Passweg, Jakob; Craddock, Charles; Blaise, Didier; Cornelissen, Jan J.; Volin, Liisa; Russell, Nigel H.; Socie, Gerard; Michallet, Mauricette; Fegueux, Nathalie; Chevallier, Patrice; Brecht, Arne; Hunault-Berger, Mathilde; Mohty, Mohamad; Esteve, Jordi; Nagler, Arnon
Contributor: University of Helsinki, Clinicum
Date: 2018-02
Language: eng
Number of pages: 10
Belongs to series: Haematologica
ISSN: 0390-6078
URI: http://hdl.handle.net/10138/233487
Abstract: Intermediate-risk cytogenetic acute myeloid leukemia with an internal tandem duplication of FLT3 (FLT3-ITD) is associated with a high risk of relapse, and is now a standard indication for allogeneic stem cell transplantation. Nevertheless, most studies supporting this strategy have been performed in young patients. To address the benefit of allogeneic transplantation in the elderly, we made a selection from the European Society for Blood and Marrow Transplantation registry of de novo intermediate-risk cytogenetic acute myeloid leukemia harboring FLT3-ITD in patients aged 60 or over and transplanted from a related or unrelated donor between January 2000 and December 2015. Two hundred and ninety-one patients were identified. Most patients received a reduced-intensity conditioning (82%), while donors consisted of an unrelated donor in 161 (55%) patients. Two hundred and twelve patients received their transplantation in first remission, 37 in second remission and 42 in a more advanced stage of the disease. The 2-year leukemia-free survival rate was 56% in patients in first remission, 22% in those in second remission and 10% in patients with active disease, respectively (P= 60 with FLT3-ITD acute myeloid leukemia in first remission, similarly to current treatment recommendations for younger patients.
Subject: CYTOGENETICALLY NORMAL AML
ACUTE MYELOGENOUS LEUKEMIA
1ST COMPLETE REMISSION
GERIATRIC ASSESSMENT
PROGNOSTIC IMPACT
NPM1 MUTATIONS
OLDER PATIENTS
ALLELIC RATIO
HEMATOLOGIC MALIGNANCIES
SORAFENIB MAINTENANCE
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
256.full.pdf 438.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record